CSIMarket
 
Obseva Sa  (OBSV)
Other Ticker:  
 
 
Price: $0.1018 $-0.02 -15.519%
Day's High: $0.1235 Week Perf: -15.03 %
Day's Low: $ 0.10 30 Day Perf: -41.56 %
Volume (M): 8,231 52 Wk High: $ 0.13
Volume (M$): $ 838 52 Wk Avg: $0.11
Open: $0.12 52 Wk Low: $0.10



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Obseva Sa
Obseva SA is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for women's reproductive health. The company is involved in the research, development, and production of drugs targeting conditions such as endometriosis, uterine fibroids, and preterm labor. Obseva aims to address the unmet medical needs of women and improve their quality of life through its products and treatments. The company utilizes advanced scientific and clinical expertise to develop safe and effective therapies, with a commitment to improving women's reproductive health worldwide.


   Company Address: Chemin des Aulx, 12 Geneva 1228
   Company Phone Number: 22 552 38 40   Stock Exchange / Ticker: NASDAQ OBSV
   OBSV is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Announcement

Navigating Uncertainty: ObsEva's Wind-Down and the Challenges of Establishing Audited IFRS Financial Statements

Published Wed, Feb 28 2024 6:00 AM UTC

TITLE: ObsEva Announces Wind-Down of Operations and Potential Effects on 2023 Audited IFRS Financial StatementsINTRODUCTIONIn an ad hoc announcement pursuant to 53 LR of the SIX Swiss Exchange, ObsEva, a biopharmaceutical company specializing in the development of innovative therapies for reproductive health and pregnancy-related conditions, has disclosed its decision to wi...

Announcement

ObsEva's Phoenix Moment: A Temporary Moratorium Illuminates the Path to Success

Published Wed, Jan 31 2024 6:00 AM UTC

Title of the Geneva Court's Temporary Moratorium Provides Hope for ObsEva's Future SuccessIn recent news, the Geneva Court has granted ObsEva, a Swiss biopharmaceutical company specialized in women's reproductive health, a temporary moratorium. This legal development, pursuant to Art. 53 LR of the SIX Swiss Exchange, has significant implications for ObsEva's future operatio...






 

Obseva Sa's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com